Horizon Pharma (HZNP) Offers H116 Net Sales, adj.-EBITDA Outlook; Provides Q1 Prescription Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Brean Capital Cuts Price Target After Horizon Pharma (HZNP) Releases Soft Guidance
April 14, 2016 9:40 AM EDTBrean Capital maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $30.00 (from $32.00), after the company provided soft 1Q and 2Q guidance. The company now expects to generate 19-20%/22-23%/57-59% of FY16 sales vs. previous consensus estimates of... More
UBS Cuts Price Target on Horizon Pharma (HZNP) After Meeting with Management
April 13, 2016 8:20 AM EDTUBS maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $24.00 (from $39.00), after meeting with management. Horizon is expecting the 1H16 to be slower than 2H16 as it needs to absorb the deductibles that patients cover before drug... More
Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) as Stock Loses Value
April 13, 2016 7:55 AM EDTPiper Jaffray maintained an Overweight rating and $44.00 price target on Horizon Pharma (NASDAQ: HZNP) after the stock loses over a quarter of its value following detail from management regarding the cadence of expected quarterly results. Management cited a higher than expected gross-to-net spreads as one driver associated with lower 1Q16 EPS contribution versus other... More
